What is the difference between ALITRETINOIN and TRETINOIN?

ALITRETINOIN and TRETINOIN are both Retinoids, so they work through the same broad mechanism. They differ in dosing, half-life, side-effect frequency, and how individual patients tolerate them. See the head-to-head sections below for the specifics.

Can ALITRETINOIN and TRETINOIN be used for the same conditions?

Both medications are prescribed for overlapping indications including symptomatic lymphedema and symptomatic pulmonary KS. Always verify with your prescriber and the current FDA label before switching.

Is PANRETIN the same as Tretinoin?

No. PANRETIN (ALITRETINOIN) and Tretinoin (TRETINOIN) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, ALITRETINOIN or TRETINOIN?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from ALITRETINOIN to TRETINOIN?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

ALITRETINOIN vs TRETINOIN

Compare ALITRETINOIN (PANRETIN) and TRETINOIN (Tretinoin) — clinical data, side effects, and patient experiences.

ALITRETINOIN

PANRETIN · Retinoid

How it works

12.1 Mechanism of Action Alitretinoin (9-cis-retinoic acid) is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptor subty...

Approved for

symptomatic lymphedema

symptomatic pulmonary KS

TopicalTablet

TRETINOIN

Tretinoin, Retin-A, Retina · Retinoid

How it works

12.1 Mechanism of Action Tretinoin induces cytodifferentiation and decreased proliferation of APL cells in culture and in vivo . In APL patients, tretinoin treatment produces an in...

Approved for

17) translocation or PML/RARα gene expression

characterized by presence of t(15

17) translocation or presence of PML/RARα gene expression

and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated.

OralTablet

Quick Comparison

ALITRETINOINTRETINOIN

Drug Class

Retinoid

Route

Topical

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ALITRETINOIN

Drug Not Working

>10%

Headache

1-10%

Vomiting

1-10%

Diarrhea

0.1-1%

Fatigue

0.1-1%

Nausea

0.1-1%

Limb Pain

0.1-1%

Condition Worsened

0.1-1%

TRETINOIN

Drug Not Working

>10%

Vomiting

1-10%

Nausea

1-10%

Rash

1-10%

Headache

1-10%

Condition Worsened

1-10%

Tingling/Numbness

1-10%

Diarrhea

1-10%

FDA Warnings

ALITRETINOIN

5 WARNINGS AND PRECAUTIONS • Embryo-Fetal Toxicity : Can cause fetal harm
Advise pregnant women of the potential risk to a fetus
Advise women of the potential risk to a fetus

TRETINOIN

5 WARNINGS AND PRECAUTIONS • Patients Without t(15;17) Translocation or PML/RARα Fusion: Tretinoin capsules may be initiated based on morphological diagnosis of APL
3 ) • Leukocytosis: Consider administering cytoreductive chemotherapy (including an anthracycline if not contraindicated or hydroxyurea) with tretinoin capsules in the setting of leukocytosis, as clinically indicated
Tretinoin capsules are a retinoid and there is an increased risk of major congenital malformations, spontaneous abortions and premature births following exposure to retinoids during pregnancy in humans
Advise pregnant women of the potential risk to a fetus

Clinical Trial Data

No head-to-head clinical studies found for ALITRETINOIN vs TRETINOIN.

ALITRETINOIN vs TRETINOIN: What You Should Know

Key Differences

Both ALITRETINOIN and TRETINOIN belong to the Retinoid class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. ALITRETINOIN is administered via Topical, whereas TRETINOIN uses Oral. Route of administration can affect onset of action and patient adherence.

Safety Considerations

ALITRETINOIN carries 3 FDA warnings. TRETINOIN carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

ALITRETINOIN vs ISOTRETINOIN→ISOTRETINOIN vs TRETINOIN→ACITRETIN vs ALITRETINOIN→ALITRETINOIN vs CLINDAMYCIN PHOSPHATE AND TRETINOIN GEL 1.2%→ALITRETINOIN vs TRETINOIN AND BENZOYL PEROXIDE→ALITRETINOIN vs CLINDAMYCIN PHOSPHATE AND TRETINOIN→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

ALITRETINOIN: DailyMed label · FAERS adverse events · ClinicalTrials.gov
TRETINOIN: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

ALITRETINOIN vs TRETINOIN

Compare ALITRETINOIN (PANRETIN) and TRETINOIN (Tretinoin) — clinical data, side effects, and patient experiences.

ALITRETINOIN

PANRETIN · Retinoid

How it works

12.1 Mechanism of Action Alitretinoin (9-cis-retinoic acid) is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptor subty...

Approved for

symptomatic lymphedema

symptomatic pulmonary KS

TopicalTablet

TRETINOIN

Tretinoin, Retin-A, Retina · Retinoid

How it works

12.1 Mechanism of Action Tretinoin induces cytodifferentiation and decreased proliferation of APL cells in culture and in vivo . In APL patients, tretinoin treatment produces an in...

Approved for

17) translocation or PML/RARα gene expression

characterized by presence of t(15

17) translocation or presence of PML/RARα gene expression

and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated.

OralTablet

Quick Comparison

ALITRETINOINTRETINOIN

Drug Class

Retinoid

Route

Topical

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ALITRETINOIN

Drug Not Working

>10%

Headache

1-10%

Vomiting

1-10%

Diarrhea

0.1-1%

Fatigue

0.1-1%

Nausea

0.1-1%

Limb Pain

0.1-1%

Condition Worsened

0.1-1%

TRETINOIN

Drug Not Working

>10%

Vomiting

1-10%

Nausea

1-10%

Rash

1-10%

Headache

1-10%

Condition Worsened

1-10%

Tingling/Numbness

1-10%

Diarrhea

1-10%

FDA Warnings

ALITRETINOIN

5 WARNINGS AND PRECAUTIONS • Embryo-Fetal Toxicity : Can cause fetal harm
Advise pregnant women of the potential risk to a fetus
Advise women of the potential risk to a fetus

TRETINOIN

5 WARNINGS AND PRECAUTIONS • Patients Without t(15;17) Translocation or PML/RARα Fusion: Tretinoin capsules may be initiated based on morphological diagnosis of APL
3 ) • Leukocytosis: Consider administering cytoreductive chemotherapy (including an anthracycline if not contraindicated or hydroxyurea) with tretinoin capsules in the setting of leukocytosis, as clinically indicated
Tretinoin capsules are a retinoid and there is an increased risk of major congenital malformations, spontaneous abortions and premature births following exposure to retinoids during pregnancy in humans
Advise pregnant women of the potential risk to a fetus

Clinical Trial Data

No head-to-head clinical studies found for ALITRETINOIN vs TRETINOIN.

ALITRETINOIN vs TRETINOIN: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.